

RESULTS OF ANNUAL GENERAL MEETING

Melbourne, Australia, 28 November 2022: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) held the 2022 Annual General Meeting (AGM) today at 10.00am (ADST).

Voting for all resolutions tabled at the AGM was conducted by poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, details of the resolutions and proxies received for the meeting are set out in the attached proxy summary.

Authorised by the Company Secretary, Mark Edwards.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARDING LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	19,610,043 96.20%	159,266 0.78%	615,866 3.02%	53,015	20,325,909 99.22%	159,266 0.78%	53,015	Carried
2 Election of Philip Powell as Non-executive Director	Ordinary	20,260,243 96.77%	60,461 0.29%	615,866 2.94%	461,308	21,069,130 99.71%	60,461 0.29%	461,308	Carried
3 Approval of 10% Placement Capacity	Special	20,529,505 96.26%	180,944 0.85%	615,866 2.89%	71,563	21,338,392 99.16%	180,944 0.84%	71,563	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.